Company Profile
Cellectar Biosciences Stock Price, News & Analysis
Company overview
Business overview
Cellectar Biosciences is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Cellectar Biosciences is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Cellectar Biosciences follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Cellectar Biosciences sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
CLRB is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Cellectar has a broader cancer-radiopharmaceutical story now, anchored by iopofosine I 131 and the CLR series. The Breakthrough Therapy Designation is the key regulatory marker, but the real question is how well the Phase 1b work and the supply-chain buildout support the next stage of development.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
- 02
Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million
Source: Cellectar Biosciences
- 03
- 04
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.